---
title: "Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294707778.md"
description: "Arcus Biosciences' 12-month average price target was lowered to $37.17 from $37.91, based on estimates from 12 analysts. Despite the cut, the consensus rating remains 'Buy' with a range of $22 to $47. At the July 31 closing price, this implies approximately 32% potential upside."
datetime: "2026-08-03T14:20:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294707778.md)
  - [en](https://longbridge.com/en/news/294707778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294707778.md)
generator: "portal-rs"
---

# Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside

-   According to estimates from 12 analysts, Arcus Biosciences, Inc. stock's average price target has fallen from $37.91 to $37.17, with forecasts ranging from $22 to $47 per share
-   Based on the Jul. 31 closing price, the updated target implies approximately 32% potential upside
-   Consensus rating remains at “Buy” across 13 covering analysts, with 10 Buys, 3 Holds and 0 Sells

Explore more price target data and ratings for Arcus Biosciences, Inc. on the , and track all previous and future analyst recommendations for Arcus Biosciences, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Arcus Biosciences Q2 revenue falls sharply on lower license income](https://longbridge.com/en/news/295013292.md)
- [Helius Medical Technologies GAAP EPS of -$0.38 misses by $0.37, revenue of $2.53M misses by $0.97M](https://longbridge.com/en/news/296076243.md)
- [SPAC ARC Group Acquisition II files for a $105 million IPO](https://longbridge.com/en/news/296541474.md)
- [These Analysts Revise Their Forecasts On Amer Sports Following Q2 Results](https://longbridge.com/en/news/296373514.md)
- [Kenvue (KVUE) Stock Looks Reasonable Despite A 37% Fair Value Gap](https://longbridge.com/en/news/296485130.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**